The Need For Digital Networks To Support Cell And Gene Therapies
By Carla Reed, president, New Creed LLC Cell and gene therapies are game changers. Critical health conditions that were once chronic or terminal are now being addressed, which is exciting news for patients and caregivers. But these therapies have a level of complexity from a supply chain perspective that needs new approaches, including a high level […]
Does Blockchain Make Sense For The Cell & Gene Therapy Supply Chain?
By Carla Reed, president, New Creed LLC Life sciences companies engaged in the transition from clinical to commercial scale are challenged by the ability of current suppliers to meet the demand for materials and services as the volume of source ingredients is increased and production capacity and yield are stabilized. In the case of cell and […]
Recalibrating The Supply Chain For Allogeneic Cell Therapies
By Carla Reed, president, New Creed LLC In November 2018, I wrote an article about establishing a supply chain for autologous cell therapies — those formulated using a patient’s own cells. This partner piece highlights considerations that need to be taken into account when developing a commercialization and supply chain strategy for allogeneic cell therapies, in which cells […]
Beyond the Mandates: The Business Value of Mass Serialization and Supply Process Visibility, Part 2
Taking the First Steps: Where to Focus and What Resources Are Needed Both U.S. and European mass serialization regulations require an integrated flow of information across the end-to-end supply chain, with related technology components for labelling, data capture, control and reporting. Irrespective of the regulations and the business drivers for a safe and secure supply […]
Beyond the Mandates: The Business Value of Mass Serialization and Supply Process Visibility, Part 1
14 August, 2018 by Carla Frances Reed, President, New Creed In 2011, I wrote a paper titled,” Beyond the Mandates,” with the intent of outlining how the proposed regulations for mass serialization (imminent for implementation with different global timelines) could provide additional value for overall supply chain visibility. Seven years later, the debate in terms […]
8 Critical Elements Of A Supply Chain Strategy — From Discovery To Commercialization
By Carla Reed, president, New Creed LLC The road from discovery of a promising molecule through the stages of clinical trials and final approval can be a challenging one. The rewards, however, are great — bringing a life-saving drug product to the point where it fulfills the promises of the early days of exploration cannot be […]